DSpace Repository

Effect of topiramate on choroidal thickness and anterior chamber parameters in the treatment of patients with migraine

Show simple item record

dc.contributor.author Gok, Mustafa
dc.contributor.author Ozdemir, Ozdemir
dc.date.accessioned 2022-08-17T06:52:22Z
dc.date.available 2022-08-17T06:52:22Z
dc.date.issued 2017
dc.identifier.uri http://doi.org/10.1080/15569527.2017.1311337
dc.identifier.uri https://www.tandfonline.com/doi/full/10.1080/15569527.2017.1311337
dc.identifier.uri http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/2610
dc.description.abstract Objective: To investigate the effects of topiramate on choroidal thickness and anterior chamber parameters using optical coherence tomography in the treatment of patients with migraine. Methods: A total of 22 eyes of 22 adults (12 females, 10 males) diagnosed with migraine and scheduled to topiramate treatment for pain control were recruited in this prospective study. Choroidal thickness (CT), anterior chamber depth (ACD), anterior chamber angle (ACA), spherical refractive equivalent (SphEq) and intraocular pressure (IOP) measurements were recorded at baseline (prior the topiramate therapy), first and second month visits for the statistical analysis. One-way ANOVA with repeated measures test was used for the statistical evaluation. Results: Mean age of the patients was 40.2 +/- 6.5 years. Mean CT at central fovea was 324 +/- 47 mm initially, 341 +/- 45 mm in the first month and 344 +/- 46 mm in the second month, thus first and second month measures were significantly higher than base values (p<0.001). There was also a slight increase in IOP values among baseline (15.5 +/- 2.4 mmHg) and follow-up visits (17.5 +/- 2.6 mmHg, 19.0 +/- 3.3 mmHg, respectively, p = 0.001). Baseline ACD (3.66 +/- 0.22 mm) measures significantly decreased at the first month (3.63 +/- 0.22 mm) and second month (3.62 +/- 0.22 mm, p = 0.009). Also, a significant reduction was detected in the first (36.2 +/- 4.9 degrees) and second month (35.9 +/- 5.1 degrees) ACA measures comparing with baseline (39.1 +/- 5.1 degrees, p = 0.05). A significant myopic shift was determined in the first and second month SphEq values (-0.08 +/- 0.6, -0.10 +/- 0.6, respectively, p = 0.05). Conclusions: The study revealed increased CT and altered anterior chamber parameters and IOP due to topiramate therapy. Therefore, the patients using topiramate should be carefully monitored by an ophthalmologist considering the possible side effects. en_US
dc.language.iso eng en_US
dc.publisher TAYLOR & FRANCIS LTD, 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND en_US
dc.relation.isversionof 10.1080/15569527.2017.1311337 en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject ANGLE-CLOSURE GLAUCOMA; ANTIEPILEPTIC DRUGS; MYOPIC SHIFT; RISK en_US
dc.subject Choroidal thickness; headaches; migraine; optical coherence tomography; topiramate en_US
dc.title Effect of topiramate on choroidal thickness and anterior chamber parameters in the treatment of patients with migraine en_US
dc.type article en_US
dc.relation.journal CUTANEOUS AND OCULAR TOXICOLOGY en_US
dc.contributor.department Ordu Üniversitesi en_US
dc.contributor.authorID 0000-0002-4833-8567 en_US
dc.contributor.authorID 0000-0002-7660-6557 en_US
dc.identifier.volume 36 en_US
dc.identifier.issue 4 en_US
dc.identifier.startpage 381 en_US
dc.identifier.endpage 386 en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account